PIK3CA and small cell lung carcinoma: We therefore tested the effects of a combination of talazoparib (PARP inhibitor) and BKM-120 (PI3K inhibitor) at clinically achievable doses in a panel of SCLC cell lines with a range of sensitivities (sensitive, intermediate and resistant) to both BKM-120 and talazoparib (sensitivity to talazoparib shown in S4 Fig).